p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin

Journal of Clinical Pathology

Volumn 55, Issue 6, 2002, Pages 461-466

  Megha, T ^a   Tosi, P ^a   Ferrari, F ^a   Benvenuto, A ^a   Bellan, C ^a   Lalinga, A V ^a   Lazzi, S ^a   Bartolommei, S ^a   Cevenini, G ^a   Leoncini, L ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; CYTOKERATIN 1; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CELL KINETICS; CELL PROLIFERATION; CORRELATION ANALYSIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MITOSIS INDEX; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; STEM CELL; TUMOR DIFFERENTIATION;

EID: 0036277515     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.55.6.461     Document Type: Article

References (47)

1. IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools
2. The p53 pathway
3. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
4. The regulation of p53 function: Steiner award lecture
5. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53
6. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
7. The molecular epidemiology of p53 gene mutations in human breast cancer
8. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis?
9. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
10. P53 gene mutations and steroid receptor status in breast cancer
11. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
12. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic values
13. Prognostic significance of p53 gene alterations in node-negative breast cancer
14. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: Correlations with established prognosis parameters and with the proliferation marker, MIB-I
15. P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
16. Expression of Bcl-2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis
17. Vimentin expression is not associated with poor prognosis in breast cancer
18. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients
19. Culture systems for study of human mammary epithelial cell proliferation, differentiation and transformation
20. Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: Relation to in vivo phenotypes and influence of medium
21. Two types of normal human breast epithelial cells derived from reduction mammoplasty. Phenotypic characterization and response to SV40 transfection
22. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas
23. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein
24. Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer
25. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction
26. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status
27. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
28. Relationship of epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients
29. Vimentin: A new prognostic parameter in breast carcinoma?
30. Correlation of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: Nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2
31. Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast
32. Abortive mitoses and nuclear fragmentation in CD30+ large cells of Hodgkin's disease
33. Counting of apoptotic cells: A methodological study in invasive breast cancer
34. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas
35. P53 in breast carcinomas: Association between presence of mutation and immunohistochemical expression using a semiquantitative approach
36. Extensive apoptosis in ductal carcinoma in situ of the breast
37. Tumor-suppressor p53: Implications for tumor development and prognosis
38. Expression of death-related genes and their relationship to loss of apoptosis in T I ductal breast carcinomas
39. Balance of cell proliferation and apoptosis in breast carcinogenesis
40. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents
41. Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms
42. Correlation of cyclin DI and Rb gene expression with apoptosis in invasive breast cancer
43. Programmed cell death by bcl-2-dependent and independent mechanisms in B-lymphomas cells
44. Proliferative life-span checkpoints: Cell-type specificity and influence on tumour biology
45. The tumor suppressor gene p53 as a regulator of proliferative life-span and tumor progression